Overview

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

Status:
Terminated

Trial end date:
2011-04-01

Target enrollment:

Participant gender:

Summary

To determine the efficacy of prasugrel versus clopidogrel for the reduction of adverse cardiovascular outcomes in patients with high platelet reactivity on clopidogrel after successful implantation of coronary drug-eluting stents. To determine the adverse event profile of prasugrel in patients with high platelet reactivity on clopidogrel after implantation of coronary drug-eluting stents. To determine the effect of prasugrel on inhibition of platelet activation in patients with high platelet reactivity on clopidogrel.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company

Collaborator:

Daiichi Sankyo Co., Ltd.

Treatments:

Clopidogrel
Prasugrel Hydrochloride
Ticlopidine